Population Pharmacokinetics and Dose–Exposure Proportionality of Edoxaban in Healthy Volunteers

Clinical Drug Investigation

Volumn 34, Issue 10, 2014, Pages 743-752

  Yin, Ophelia Q P ^a   Miller, Raymond ^a  

^a DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDOXABAN; MOXIFLOXACIN; PLACEBO; QUINIDINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; FEMALE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GENDER; HUMAN; MALE; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); POPULATION MODEL; POPULATION PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; ADOLESCENT; BIOAVAILABILITY; BIOLOGICAL MODEL; DOSE RESPONSE; META ANALYSIS; MIDDLE AGED; NONLINEAR SYSTEM; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PYRIDINES; SEX FACTORS; THIAZOLES; YOUNG ADULT;

EID: 84919328154     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0229-7     Document Type: Article

References (20)

1. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–9.
2. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose–response study. Thromb Haemost. 2010;104:642–9.
3. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633–41.
4. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635–41.
5. Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
6. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15.
7. A randomized, open-label, parallel-group, multi-center study for the evaluation of efficacy and safety of edoxaban monotherapy versus low molecular weight (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis (eTRIS). http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01662908. Accessed 25 Feb 2014.
8. Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:358–66.
9. Mendell J, Tachibana M, Shi M, et al. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol. 2011;51:687–94.
10. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743–53.
11. Bathala MS, Masumoto H, Oguma T, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250–5.
12. Mendell J, Basavapathrisni R, Swcaringen D, et al. Thorough QT/QTc study with edoxaban to evaluate effect of therapeutic and supratherapeutic exposure on QTc interval duration in healthy subjects. J Clin Pharmacol. 2009;49:1122.
13. Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor. Am J Cardiovasc Drugs. 2013;13:331–42.
14. Oguma T, Masumoto H, Yoshigae Y, et al. LC-MS/MS bioanalytical method for the determination of edoxaban in human plasma. AAPS J. 2010;S2:Abstract R6377.
15. Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51–64.
16. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.
17. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)–a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85–94.
18. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.
19. Ahn JE, Karlsson MO, Dunne A, et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008;35:401–21.
20. Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76:1840–7.